Company intelligence / Profile preview

EIPICO

10th of Ramadan City, Egypteipico.com.eg ↗

Ownership: Private
Employees: ~5300
Development stage: Commercial

Overview

Leading Egyptian pharmaceutical company with significant market share in antibiotics, lyophilized products, and spansule capsules. Recently expanded into biologicals and biosimilars with EIPICO 3 facility.

Therapeutic areas: Other
Modalities: Small moleculesBiosimilarsBiologicalsMonoclonal antibodies (mAb)Recombinant proteins
Industry: Biotech

Drug pipeline

1 asset

Epinosine B Forte

Partnerships

License agreements with international pharmaceutical companies

Beyond the preview

Go deeper on EIPICO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EIPICO.

Explore the full profile